|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�ʴ�ϸ�� |
|
����άϸ�� |
|
ӲƤ�� |
| ��������������� | |
|
���� |
|
���̸� |
| PubMed | |
|
Article by |
|
Article by |
�ʴ�ϸ����ӲƤ��
����, ���̸�
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
�ʴ�ϸ���ǽ鵼�ٷ��ͱ�̬��Ӧ����֢����Ҫ��Ŧ,����ʼ��������֢��Ӧ,������ּ�������֢����.��һЩ��ԭ��ά������ֳ�ļ������۸�������ϡ�ӲƤ��������,���ɹ۲쵽�ʴ�ϸ���ľۼ��ͼ���.�ʴ�ϸ��ͨ�����������弰�ϳɡ��ͷŵ�ϸ�����Ӻ���֢����,����֯�ؽ��ͽ�ԭ��ά�ֻ�����ֳ����������Ҫ����.
[2] Furst DE,Clements PJ.Hypothesis for the pathogenesis of systemic sclerosis.J Rheumatol Suppl,1997,48:53-57.
[3] Costa J J,Demetri GD,Harrist TJ,et al.Recombinant human stem cell factor(kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo.J Exp Med,1996,183:2681-2686.
[4] Benoist C,Mathis D.Mast cells in autoimmune disease.Nature,2002,420:875-878.
[5] Galli SJ.New concepts about the mast cell.N Engl J Med,1993,328:257-265.
[6] Craig SS,Schechter NM,Schwartz LB.Ultrastructural analysis of maturing human T and TC mast cells in situ.Lab Invest,1989,60:147-157.
[7] Marshall JS,McCurdy JD,Olynych T.Toll-like receptor-mediated activation of mast cells:implications for allergic disease? Int Arch Allergy Immunol,2003,132:87-97.
[8] Valent P,Schernthaner GH,Sperr WR,et al.Variable expression of activation-linked surface antigens on human mast cells in health and disease.Immunol Rev,2001,179:74-81.
[9] Falanga V,Soter NA,Altman RD,et al.Elevated plasma histamine levels in systemic sclerosis(scleroderma).Arch Dermatol,1990,126:336-338.
[10] Gailit J,Marchese MJ,Kew RR,et al.The differentiation and function of myofibroblasts is regulated by mast cell mediators.J Invest Dermatol,2001,117:1113-1119.
[11] Warren JS,Mandel DM,Johnson K J,et al.Evidence for the role of platelet-activating factor in immune complex vasculitis in the rat.J Clin Invest,1989,83:669-678.
[12] Akimoto S,Ishikawa O,Igarashi Y,et al.Dermal mast cells in scleroderma:their skin density,tryptase/chymase phenotypes and degranulation.Br J Dermatol,1998,138:399-406.
[13] Ruoslahti E.Proteoglycans in cell regulation.J Biol Chem,1989,264:13369-13372.
[14] Yamamoto T,Takagawa S,Katayama I,et al.Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma.Clin Immunol,1999,92:6-13.
[15] Abe M,Kurosawa M,Ishikawa O,et al.Effect of mast cell-derived mediators and mast cell-related neutral proteases on human dermal fibroblast proliferation and type �� collagen production.J Allergy Clin Immunol,2000,106:S78-S84.
[16] Claman HN.Mast cell changes in a case of rapidly progressive scleroderma-ultrastructural analysis.J Invest Dermatol,1989,92:290-295.
[17] Ozbilgin MK,Inan S.The roles of transforming growth factor type beta3(TGF-beta3) and mast cells in the pathogenesis of scleroderma.Clin Rheumatol,2003,22:189-195.
[18] Yamamoto T,Hartmann K,Eckes B,et al.Mast cells enhance contraction of three-dimensional collagen lattices by fibroblasts by cell-cell interaction:role of stem cell factor/c-kit.Immunology,2000,99:435-439.
[19] Abe M,Yokoyama Y,Amano H,et al.Effect of activated human mast cells and mast cell-derived mediators on proliferation,type I collagen production and glycosaminoglycans synthesis by human dermal fibroblasts.Eur J Dermatol,2002,12:340-346.
[20] Yamamoto T,Takagawa S,Nishioka K.Mast cell-independent increase of type �� collagen expression in experimental scleroderma induced by bleomycin.Arch Dermatol Res,2001,293:532-536.